Review



anti cd107a pe  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Miltenyi Biotec anti cd107a pe
    Anti Cd107a Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 55 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd107a+pe/pm42455847-56-4-6?v=Miltenyi+Biotec
    Average 93 stars, based on 55 article reviews
    anti cd107a pe - by Bioz Stars, 2026-08
    93/100 stars

    Images



    Similar Products

    93
    Miltenyi Biotec anti cd107a pe
    Anti Cd107a Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd107a+pe/pm42455847-56-4-6?v=Miltenyi+Biotec
    Average 93 stars, based on 1 article reviews
    anti cd107a pe - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    94
    Bio-Rad bio rad laboratories mca2315a647 intracellular ifnγ p2g10 mouse igg1 pe
    Bio Rad Laboratories Mca2315a647 Intracellular Ifnγ P2g10 Mouse Igg1 Pe, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd107a+pe/pm41759556-227-36-36?v=Bio-Rad
    Average 94 stars, based on 1 article reviews
    bio rad laboratories mca2315a647 intracellular ifnγ p2g10 mouse igg1 pe - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology pe anti mouse cd107a lamp 1 antibody
    Pe Anti Mouse Cd107a Lamp 1 Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd107a+pe/bio_rxiv__64898__2026__02__21__707223-274-203-209?v=Elabscience+Biotechnology
    Average 94 stars, based on 1 article reviews
    pe anti mouse cd107a lamp 1 antibody - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec pe labeled anti cd107a
    Pe Labeled Anti Cd107a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd107a+pe/pmc12537779-94-7-11?v=Miltenyi+Biotec
    Average 93 stars, based on 1 article reviews
    pe labeled anti cd107a - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec mabs anti human cd107a
    Differential responses of CAR T cells and CAR NK cells upon exposure to self-antigens. (A-B) viability assessment of the CAR-negative (A) and CAR-positive (B) population was conducted using PI staining at 3, 6, and 10 days post-transduction, analyzed via flow cytometry. (C-E) flow cytometric analysis of surface expression in the CAR-positive population for (C) <t>CD107a,</t> (D) LAG-3, and (E) PD-1 at 3, 6, and 10 days post-transduction. Data are presented as mean ± SD, with BCMA CAR: n = 17; SLAMF7 CAR: n = 17; CD38 CAR: n = 4. Statistical significance was determined using ordinary two-way ANOVA followed by Dunnett’s multiple comparison test. Asterisks (*) denote a significant increase ( p ≤ 0.05) in CD38 CAR-engineered cells compared to the corresponding BCMA CAR-engineered group. Hash symbols (#) indicate a significant increase ( p ≤ 0.05) in SLAMF7 CAR-engineered cells compared to the BCMA CAR-engineered group.
    Mabs Anti Human Cd107a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd107a+pe/pmc12416173-83-8-15?v=Miltenyi+Biotec
    Average 93 stars, based on 1 article reviews
    mabs anti human cd107a - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec anti cd107a pe vio770
    Differential responses of CAR T cells and CAR NK cells upon exposure to self-antigens. (A-B) viability assessment of the CAR-negative (A) and CAR-positive (B) population was conducted using PI staining at 3, 6, and 10 days post-transduction, analyzed via flow cytometry. (C-E) flow cytometric analysis of surface expression in the CAR-positive population for (C) <t>CD107a,</t> (D) LAG-3, and (E) PD-1 at 3, 6, and 10 days post-transduction. Data are presented as mean ± SD, with BCMA CAR: n = 17; SLAMF7 CAR: n = 17; CD38 CAR: n = 4. Statistical significance was determined using ordinary two-way ANOVA followed by Dunnett’s multiple comparison test. Asterisks (*) denote a significant increase ( p ≤ 0.05) in CD38 CAR-engineered cells compared to the corresponding BCMA CAR-engineered group. Hash symbols (#) indicate a significant increase ( p ≤ 0.05) in SLAMF7 CAR-engineered cells compared to the BCMA CAR-engineered group.
    Anti Cd107a Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd107a+pe/pmc12416173-65-9-15?v=Miltenyi+Biotec
    Average 93 stars, based on 1 article reviews
    anti cd107a pe vio770 - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec cd107a
    In vitro functional assays and immunogenicity assay. (a) Proliferation assay. HUVEC were plated and cultured in typical HUVEC media (unstressed, Control +) and in protein‐depleted media (stress condition). Stressed HUVEC were untreated (Control –) or treated with 50 µL of final product or 50 µL of PBS 1X (vehicle control). HUVEC proliferation was quantified by measuring BrdU uptake. Values were double normalised (baseline [negative control] subtracted, and normalised to the positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 5 technical replicates). (b) Cardiomyocyte survival assay. This test is a staurosporine‐induced cardiotoxicity assay. Cardiomyocytes were exposed to NucSpot Live 650 dye without staurosporine (Control +), with staurosporine alone (Control –) or with stauroporine and increasing concentrations of the final product. At the 24‐h time‐point, cell counts were determined by Incucyte. Values were double normalised (baseline [negative control] subtracted, and normalised to the positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 3 technical replicates). (c) Scratch wound healing assay. After establishing a monolayer of HUVEC, a scratch was induced using the Wound Maker according to the manufacturer's directions. Following the scratch, HUVEC were cultured in typical HUVEC media (unstressed, Control +) and in protein depleted (stress condition) media. Stressed HUVEC were untreated (Control –) or treated with final product. Plates were imaged by Incucyte at T0 and every 2 h up to 18‐h. Representative images taken on the Incucyte depicting individual wells are shown immediately after the scratch (T0) and 18 h post‐treatment (T18). Data in the figure represent a single, representative experiment. (d) Scratch wound healing assay. The results of HUVEC scratch wound healing assay described above were determined using the Scratch Wound Healing Module. Normalised wound confluence results at the 18‐h timepoint were double normalised (baseline [negative control] subtracted, and normalised to positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 5 technical replicates). (e) NK cell degranulation. The percent of human NK cells expressing <t>CD107a</t> was measured by flow cytometry. Human NK cells were cultured in the presence of human K562 cells (positive control), PMA/ionomycin 1X (second positive control) or 50 µL of PBS 1X (vehicle control) or 50 µL of final product. In presence of final product, there is a dramatic absence of expression of CD107a compared with the positive controls. Data in the figure represent a single, representative experiment (average +/– SD; n = 3 technical replicates). (f) PBMC alloreactive activation. The levels of multiple cytokines, IFN‐γ, and IL‐2 were measured by flow cytometry. Human PBMC were cultured in the presence of PMA/ionomycin 1X (positive control), 50 µL of PBS 1X (vehicle control) or 50 µL of the final product. Data in the figure represent a single, representative experiment.
    Cd107a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd107a+pe/pmc12365392-222-26-42?v=Miltenyi+Biotec
    Average 93 stars, based on 1 article reviews
    cd107a - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology elabscience apc anti human cd107a lamp 1
    In vitro functional assays and immunogenicity assay. (a) Proliferation assay. HUVEC were plated and cultured in typical HUVEC media (unstressed, Control +) and in protein‐depleted media (stress condition). Stressed HUVEC were untreated (Control –) or treated with 50 µL of final product or 50 µL of PBS 1X (vehicle control). HUVEC proliferation was quantified by measuring BrdU uptake. Values were double normalised (baseline [negative control] subtracted, and normalised to the positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 5 technical replicates). (b) Cardiomyocyte survival assay. This test is a staurosporine‐induced cardiotoxicity assay. Cardiomyocytes were exposed to NucSpot Live 650 dye without staurosporine (Control +), with staurosporine alone (Control –) or with stauroporine and increasing concentrations of the final product. At the 24‐h time‐point, cell counts were determined by Incucyte. Values were double normalised (baseline [negative control] subtracted, and normalised to the positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 3 technical replicates). (c) Scratch wound healing assay. After establishing a monolayer of HUVEC, a scratch was induced using the Wound Maker according to the manufacturer's directions. Following the scratch, HUVEC were cultured in typical HUVEC media (unstressed, Control +) and in protein depleted (stress condition) media. Stressed HUVEC were untreated (Control –) or treated with final product. Plates were imaged by Incucyte at T0 and every 2 h up to 18‐h. Representative images taken on the Incucyte depicting individual wells are shown immediately after the scratch (T0) and 18 h post‐treatment (T18). Data in the figure represent a single, representative experiment. (d) Scratch wound healing assay. The results of HUVEC scratch wound healing assay described above were determined using the Scratch Wound Healing Module. Normalised wound confluence results at the 18‐h timepoint were double normalised (baseline [negative control] subtracted, and normalised to positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 5 technical replicates). (e) NK cell degranulation. The percent of human NK cells expressing <t>CD107a</t> was measured by flow cytometry. Human NK cells were cultured in the presence of human K562 cells (positive control), PMA/ionomycin 1X (second positive control) or 50 µL of PBS 1X (vehicle control) or 50 µL of final product. In presence of final product, there is a dramatic absence of expression of CD107a compared with the positive controls. Data in the figure represent a single, representative experiment (average +/– SD; n = 3 technical replicates). (f) PBMC alloreactive activation. The levels of multiple cytokines, IFN‐γ, and IL‐2 were measured by flow cytometry. Human PBMC were cultured in the presence of PMA/ionomycin 1X (positive control), 50 µL of PBS 1X (vehicle control) or 50 µL of the final product. Data in the figure represent a single, representative experiment.
    Elabscience Apc Anti Human Cd107a Lamp 1, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd107a+pe/pmc12357428__12915_2025_2355_MOESM1_ESM-6-41-41?v=Elabscience+Biotechnology
    Average 94 stars, based on 1 article reviews
    elabscience apc anti human cd107a lamp 1 - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec cd107a pe mab
    In vitro functional assays and immunogenicity assay. (a) Proliferation assay. HUVEC were plated and cultured in typical HUVEC media (unstressed, Control +) and in protein‐depleted media (stress condition). Stressed HUVEC were untreated (Control –) or treated with 50 µL of final product or 50 µL of PBS 1X (vehicle control). HUVEC proliferation was quantified by measuring BrdU uptake. Values were double normalised (baseline [negative control] subtracted, and normalised to the positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 5 technical replicates). (b) Cardiomyocyte survival assay. This test is a staurosporine‐induced cardiotoxicity assay. Cardiomyocytes were exposed to NucSpot Live 650 dye without staurosporine (Control +), with staurosporine alone (Control –) or with stauroporine and increasing concentrations of the final product. At the 24‐h time‐point, cell counts were determined by Incucyte. Values were double normalised (baseline [negative control] subtracted, and normalised to the positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 3 technical replicates). (c) Scratch wound healing assay. After establishing a monolayer of HUVEC, a scratch was induced using the Wound Maker according to the manufacturer's directions. Following the scratch, HUVEC were cultured in typical HUVEC media (unstressed, Control +) and in protein depleted (stress condition) media. Stressed HUVEC were untreated (Control –) or treated with final product. Plates were imaged by Incucyte at T0 and every 2 h up to 18‐h. Representative images taken on the Incucyte depicting individual wells are shown immediately after the scratch (T0) and 18 h post‐treatment (T18). Data in the figure represent a single, representative experiment. (d) Scratch wound healing assay. The results of HUVEC scratch wound healing assay described above were determined using the Scratch Wound Healing Module. Normalised wound confluence results at the 18‐h timepoint were double normalised (baseline [negative control] subtracted, and normalised to positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 5 technical replicates). (e) NK cell degranulation. The percent of human NK cells expressing <t>CD107a</t> was measured by flow cytometry. Human NK cells were cultured in the presence of human K562 cells (positive control), PMA/ionomycin 1X (second positive control) or 50 µL of PBS 1X (vehicle control) or 50 µL of final product. In presence of final product, there is a dramatic absence of expression of CD107a compared with the positive controls. Data in the figure represent a single, representative experiment (average +/– SD; n = 3 technical replicates). (f) PBMC alloreactive activation. The levels of multiple cytokines, IFN‐γ, and IL‐2 were measured by flow cytometry. Human PBMC were cultured in the presence of PMA/ionomycin 1X (positive control), 50 µL of PBS 1X (vehicle control) or 50 µL of the final product. Data in the figure represent a single, representative experiment.
    Cd107a Pe Mab, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd107a+pe/pm40701264-103-27-30?v=Miltenyi+Biotec
    Average 93 stars, based on 1 article reviews
    cd107a pe mab - by Bioz Stars, 2026-08
    93/100 stars
      Buy from Supplier

    Image Search Results


    Differential responses of CAR T cells and CAR NK cells upon exposure to self-antigens. (A-B) viability assessment of the CAR-negative (A) and CAR-positive (B) population was conducted using PI staining at 3, 6, and 10 days post-transduction, analyzed via flow cytometry. (C-E) flow cytometric analysis of surface expression in the CAR-positive population for (C) CD107a, (D) LAG-3, and (E) PD-1 at 3, 6, and 10 days post-transduction. Data are presented as mean ± SD, with BCMA CAR: n = 17; SLAMF7 CAR: n = 17; CD38 CAR: n = 4. Statistical significance was determined using ordinary two-way ANOVA followed by Dunnett’s multiple comparison test. Asterisks (*) denote a significant increase ( p ≤ 0.05) in CD38 CAR-engineered cells compared to the corresponding BCMA CAR-engineered group. Hash symbols (#) indicate a significant increase ( p ≤ 0.05) in SLAMF7 CAR-engineered cells compared to the BCMA CAR-engineered group.

    Journal: Oncoimmunology

    Article Title: Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies

    doi: 10.1080/2162402X.2025.2546443

    Figure Lengend Snippet: Differential responses of CAR T cells and CAR NK cells upon exposure to self-antigens. (A-B) viability assessment of the CAR-negative (A) and CAR-positive (B) population was conducted using PI staining at 3, 6, and 10 days post-transduction, analyzed via flow cytometry. (C-E) flow cytometric analysis of surface expression in the CAR-positive population for (C) CD107a, (D) LAG-3, and (E) PD-1 at 3, 6, and 10 days post-transduction. Data are presented as mean ± SD, with BCMA CAR: n = 17; SLAMF7 CAR: n = 17; CD38 CAR: n = 4. Statistical significance was determined using ordinary two-way ANOVA followed by Dunnett’s multiple comparison test. Asterisks (*) denote a significant increase ( p ≤ 0.05) in CD38 CAR-engineered cells compared to the corresponding BCMA CAR-engineered group. Hash symbols (#) indicate a significant increase ( p ≤ 0.05) in SLAMF7 CAR-engineered cells compared to the BCMA CAR-engineered group.

    Article Snippet: To assess degranulation, the cells were stained with mAbs anti-human CD107a (LAMP-1, PE-Vio® 770, REAfinityTM, Miltenyi, Bergisch Gladbach, Germany).

    Techniques: Staining, Transduction, Flow Cytometry, Expressing, Comparison

    Modulation of CAR NK-mediated cytotoxicity by inhibitory receptors and target antigen density. (A) schematic representation of NK cell interaction outcomes with target cells. Left box: tolerance mechanism: equilibrium between stimulatory and inhibitory receptor signaling results in target cell preservation. Middlebox: missing-self mechanism (NKG2A blockade): NK cell activation and subsequent target cell lysis due to inhibition of NKG2A signaling. Right box: missing-self mechanism (HLA-E blockade): NK cell activation and target cell lysis resulting from interference with inhibitory KIR receptor signaling. (B) SLAMF7 CAR NK cells were co-cultured immediately post-transduction with or without monoclonal antibodies targeting CD159a alone, HLA-ABC alone, or in combination. Flow cytometric analysis was performed at 3, 6, and 10 days post-transduction to assess cell counts, CAR expression, and cell death of the CAR-negative and CAR-positive population via PI staining. Data of cell counts and CAR expression are presented as mean ± SEM log2 fold change to mitigate donor variation; n = 5. Data of cell death are presented as mean ± SD; n = 5. Statistical significance was determined using two-way ANOVA followed by Sidak’s multiple comparison test (* p ≤ 0.05). (C) evaluation of CD107a surface expression on SLAMF7 CAR T or SLAMF7 CAR NK cells at 3 days post-transduction in response to varying SLAMF7 protein concentrations, with or without bead stimulation. Additionally, one experimental condition included co-incubation with CD159a monoclonal antibody and anti-mouse FAB antibody to induce cross-linking of the SLAMF7 protein staining. Data are presented as mean ± SEM; n = 6. Statistical significance was determined using ordinary one-way ANOVA followed by Dunnett’s multiple comparison test (* p ≤ 0.05).

    Journal: Oncoimmunology

    Article Title: Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies

    doi: 10.1080/2162402X.2025.2546443

    Figure Lengend Snippet: Modulation of CAR NK-mediated cytotoxicity by inhibitory receptors and target antigen density. (A) schematic representation of NK cell interaction outcomes with target cells. Left box: tolerance mechanism: equilibrium between stimulatory and inhibitory receptor signaling results in target cell preservation. Middlebox: missing-self mechanism (NKG2A blockade): NK cell activation and subsequent target cell lysis due to inhibition of NKG2A signaling. Right box: missing-self mechanism (HLA-E blockade): NK cell activation and target cell lysis resulting from interference with inhibitory KIR receptor signaling. (B) SLAMF7 CAR NK cells were co-cultured immediately post-transduction with or without monoclonal antibodies targeting CD159a alone, HLA-ABC alone, or in combination. Flow cytometric analysis was performed at 3, 6, and 10 days post-transduction to assess cell counts, CAR expression, and cell death of the CAR-negative and CAR-positive population via PI staining. Data of cell counts and CAR expression are presented as mean ± SEM log2 fold change to mitigate donor variation; n = 5. Data of cell death are presented as mean ± SD; n = 5. Statistical significance was determined using two-way ANOVA followed by Sidak’s multiple comparison test (* p ≤ 0.05). (C) evaluation of CD107a surface expression on SLAMF7 CAR T or SLAMF7 CAR NK cells at 3 days post-transduction in response to varying SLAMF7 protein concentrations, with or without bead stimulation. Additionally, one experimental condition included co-incubation with CD159a monoclonal antibody and anti-mouse FAB antibody to induce cross-linking of the SLAMF7 protein staining. Data are presented as mean ± SEM; n = 6. Statistical significance was determined using ordinary one-way ANOVA followed by Dunnett’s multiple comparison test (* p ≤ 0.05).

    Article Snippet: To assess degranulation, the cells were stained with mAbs anti-human CD107a (LAMP-1, PE-Vio® 770, REAfinityTM, Miltenyi, Bergisch Gladbach, Germany).

    Techniques: Preserving, Activation Assay, Lysis, Inhibition, Cell Culture, Transduction, Bioprocessing, Expressing, Staining, Comparison, Incubation

    In vitro functional assays and immunogenicity assay. (a) Proliferation assay. HUVEC were plated and cultured in typical HUVEC media (unstressed, Control +) and in protein‐depleted media (stress condition). Stressed HUVEC were untreated (Control –) or treated with 50 µL of final product or 50 µL of PBS 1X (vehicle control). HUVEC proliferation was quantified by measuring BrdU uptake. Values were double normalised (baseline [negative control] subtracted, and normalised to the positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 5 technical replicates). (b) Cardiomyocyte survival assay. This test is a staurosporine‐induced cardiotoxicity assay. Cardiomyocytes were exposed to NucSpot Live 650 dye without staurosporine (Control +), with staurosporine alone (Control –) or with stauroporine and increasing concentrations of the final product. At the 24‐h time‐point, cell counts were determined by Incucyte. Values were double normalised (baseline [negative control] subtracted, and normalised to the positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 3 technical replicates). (c) Scratch wound healing assay. After establishing a monolayer of HUVEC, a scratch was induced using the Wound Maker according to the manufacturer's directions. Following the scratch, HUVEC were cultured in typical HUVEC media (unstressed, Control +) and in protein depleted (stress condition) media. Stressed HUVEC were untreated (Control –) or treated with final product. Plates were imaged by Incucyte at T0 and every 2 h up to 18‐h. Representative images taken on the Incucyte depicting individual wells are shown immediately after the scratch (T0) and 18 h post‐treatment (T18). Data in the figure represent a single, representative experiment. (d) Scratch wound healing assay. The results of HUVEC scratch wound healing assay described above were determined using the Scratch Wound Healing Module. Normalised wound confluence results at the 18‐h timepoint were double normalised (baseline [negative control] subtracted, and normalised to positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 5 technical replicates). (e) NK cell degranulation. The percent of human NK cells expressing CD107a was measured by flow cytometry. Human NK cells were cultured in the presence of human K562 cells (positive control), PMA/ionomycin 1X (second positive control) or 50 µL of PBS 1X (vehicle control) or 50 µL of final product. In presence of final product, there is a dramatic absence of expression of CD107a compared with the positive controls. Data in the figure represent a single, representative experiment (average +/– SD; n = 3 technical replicates). (f) PBMC alloreactive activation. The levels of multiple cytokines, IFN‐γ, and IL‐2 were measured by flow cytometry. Human PBMC were cultured in the presence of PMA/ionomycin 1X (positive control), 50 µL of PBS 1X (vehicle control) or 50 µL of the final product. Data in the figure represent a single, representative experiment.

    Journal: Journal of Extracellular Vesicles

    Article Title: GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial

    doi: 10.1002/jev2.70145

    Figure Lengend Snippet: In vitro functional assays and immunogenicity assay. (a) Proliferation assay. HUVEC were plated and cultured in typical HUVEC media (unstressed, Control +) and in protein‐depleted media (stress condition). Stressed HUVEC were untreated (Control –) or treated with 50 µL of final product or 50 µL of PBS 1X (vehicle control). HUVEC proliferation was quantified by measuring BrdU uptake. Values were double normalised (baseline [negative control] subtracted, and normalised to the positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 5 technical replicates). (b) Cardiomyocyte survival assay. This test is a staurosporine‐induced cardiotoxicity assay. Cardiomyocytes were exposed to NucSpot Live 650 dye without staurosporine (Control +), with staurosporine alone (Control –) or with stauroporine and increasing concentrations of the final product. At the 24‐h time‐point, cell counts were determined by Incucyte. Values were double normalised (baseline [negative control] subtracted, and normalised to the positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 3 technical replicates). (c) Scratch wound healing assay. After establishing a monolayer of HUVEC, a scratch was induced using the Wound Maker according to the manufacturer's directions. Following the scratch, HUVEC were cultured in typical HUVEC media (unstressed, Control +) and in protein depleted (stress condition) media. Stressed HUVEC were untreated (Control –) or treated with final product. Plates were imaged by Incucyte at T0 and every 2 h up to 18‐h. Representative images taken on the Incucyte depicting individual wells are shown immediately after the scratch (T0) and 18 h post‐treatment (T18). Data in the figure represent a single, representative experiment. (d) Scratch wound healing assay. The results of HUVEC scratch wound healing assay described above were determined using the Scratch Wound Healing Module. Normalised wound confluence results at the 18‐h timepoint were double normalised (baseline [negative control] subtracted, and normalised to positive control). Data in the figure represent a single, representative experiment (average +/– SD; n = 5 technical replicates). (e) NK cell degranulation. The percent of human NK cells expressing CD107a was measured by flow cytometry. Human NK cells were cultured in the presence of human K562 cells (positive control), PMA/ionomycin 1X (second positive control) or 50 µL of PBS 1X (vehicle control) or 50 µL of final product. In presence of final product, there is a dramatic absence of expression of CD107a compared with the positive controls. Data in the figure represent a single, representative experiment (average +/– SD; n = 3 technical replicates). (f) PBMC alloreactive activation. The levels of multiple cytokines, IFN‐γ, and IL‐2 were measured by flow cytometry. Human PBMC were cultured in the presence of PMA/ionomycin 1X (positive control), 50 µL of PBS 1X (vehicle control) or 50 µL of the final product. Data in the figure represent a single, representative experiment.

    Article Snippet: After 18 h, cells were harvested, washed and stained with CD16‐PE, CD56‐PE, CD8‐APC Vio770, CD4 Viogreen specific antibodies and 7‐AAD (Miltenyi Biotec), and the expression of CD107a was analysed on CD16 + CD56 + human NK cells using a MQ10 Flow Cytometer (Miltenyi Biotec).

    Techniques: In Vitro, Functional Assay, Immunopeptidomics, Proliferation Assay, Cell Culture, Control, Negative Control, Positive Control, Clonogenic Cell Survival Assay, Wound Healing Assay, Expressing, Flow Cytometry, Activation Assay